Trial Profile
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2022
Price :
$35
*
At a glance
- Drugs Vesatolimod (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Gilead Sciences
- 16 Feb 2022 Results of exploratory analysis assessing Immunological and Glycomic Correlates of Time-to-Hiv-Rebound in Viremic Controllers, presented at the 29th Conference on Retroviruses and Opportunistic Infections
- 12 Oct 2020 Results assessing safety, pharmacokinetics, and pharmacodynamics of vesatolimod in adults living with HIV-1 published in the Clinical Infectious Diseases
- 11 Mar 2020 Results (n=25) assessing Safety and Analytic Treatment Interruption Outcomes of Vesatolimod in Hiv Controllers, presented at the 27th Conference on Retroviruses and Opportunistic Infections